CTA
AMRX icon

Carillon Tower Advisers’s Amneal Pharmaceuticals AMRX Stock Holding History

Carillon Tower Advisers’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-102,119
Closed -$1.38M – 462
2018
Q4 		$1.38M Sell
102,119
-1,000
-1% -$18K 0.01% 448
2018
Q3 		$2.29M Buy
103,119
+2,011
+2% +$42.3K 0.02% 411
2018
Q2 		$1.66M Buy
+101,108
New +$1.77M 0.01% 449

Other funds holding AMRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
TG
TCW Group Los Angeles, California $14.9B AUM 46.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Carillon Tower Advisers's AMRX Position: Q1 2019 in Review

Carillon Tower Advisers sold out of Amneal Pharmaceuticals (AMRX) in Q1 2019, closing a stake of 102,119 shares — an estimated $1.38M sold.

Carillon Tower Advisers first reported a position in AMRX in Q2 2018 and held it in 3 quarters. The position peaked at $2.29M in Q3 2018. 164 funds tracked by Wall St. Rank hold AMRX as of Q1 2019.

  • Carillon Tower Advisers reported no remaining Amneal Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Carillon Tower Advisers sold 102,119 Amneal Pharmaceuticals shares in Q1 2019, an estimated $1.38M.
  • Carillon Tower Advisers first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Carillon Tower Advisers's Amneal Pharmaceuticals position peaked at $2.29M in Q3 2018.
  • 164 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2019.

Based on Carillon Tower Advisers's 13F filing for Q1 2019, filed 3 May 2019.